echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Xuanzhu Biotechnology introduced single-target AXL inhibitors and only one domestic company applied for clinical application

    Xuanzhu Biotechnology introduced single-target AXL inhibitors and only one domestic company applied for clinical application

    • Last Update: 2021-10-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Rubik's Cube Info

    Author: Shi Bei

    On September 24, Sihuan Pharmaceutical issued an announcement that its subsidiary Xuanzhu Biotechnology and SignalChem Life Sciences signed a cooperation and licensing agreement on the development and commercialization rights of the AXL inhibitor SLC-391 in Greater China


    AXL is a member of the TAM family of tyrosine protein kinases (Tyro3, ​​AXL and Mer).


    SLC-391 is an effective, highly selective, and oral small molecule AXL inhibitor.


    Earlier, SignalChem has reached a cooperation with Merck, and the two parties jointly conducted an evaluation of the effectiveness of the combination of SLC-391 and Keytruda for the treatment of advanced NSCLC


    In China, many companies are developing AXL multi-target kinase inhibitors, but only one company has introduced a single-target selective AXL inhibitor 3D-229 (AVB-500) from the American company Aravive for a total of 219 million US dollars.


    The advantage of AVB-500 is that it has a high affinity for GAS6 ligand, which solves the off-target toxicity caused by the low selectivity of multi-target AXL kinase inhibitors, the problem of tumor cell resistance and the low affinity of monoclonal antibodies, which is not enough to destroy The interaction problem between natural GAS6/AXL


    Previously, AVB-500 has shown potential efficacy in a phase Ib clinical trial for patients with platinum-resistant ovarian cancer (PROC)


    At present, clinical trials of AVB-500 for renal cell carcinoma and urothelial cancer are also underway, and have obtained fast track qualification granted by the FDA for platinum-resistant recurrent ovarian cancer indications.


    Source: Aravive official website

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.